Search hospitals

>

California

>

San Diego

Rady Children's Hospital - San Diego

Claim this profile

San Diego, California 92123

Global Leader in Acute Lymphoblastic Leukemia

Global Leader in Brain Tumor

Conducts research for Cancer

Conducts research for Neuroblastoma

Conducts research for Leukemia

494 reported clinical trials

42 medical researchers

Photo of Rady Children's Hospital - San Diego in San DiegoPhoto of Rady Children's Hospital - San Diego in San DiegoPhoto of Rady Children's Hospital - San Diego in San Diego

Summary

Rady Children's Hospital - San Diego is a medical facility located in San Diego, California. This center is recognized for care of Acute Lymphoblastic Leukemia, Brain Tumor, Cancer, Neuroblastoma, Leukemia and other specialties. Rady Children's Hospital - San Diego is involved with conducting 494 clinical trials across 791 conditions. There are 42 research doctors associated with this hospital, such as William D. Roberts, Deborah Schiff, Eric Anderson, and John Crawford, MD, MS.

Area of expertise

1

Acute Lymphoblastic Leukemia

Global Leader

Rady Children's Hospital - San Diego has run 52 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:

Stage II
CD19 positive
CD7 positive
2

Brain Tumor

Global Leader

Rady Children's Hospital - San Diego has run 52 trials for Brain Tumor. Some of their research focus areas include:

Stage I
Stage II
Stage IV

Top PIs

Clinical Trials running at Rady Children's Hospital - San Diego

Neuroblastoma

Cancer

Leukemia

Testicular cancer

Brain Tumor

Solid Tumors

Prader-Willi Syndrome

Brain Cancer

Acute Lymphoblastic Leukemia

Acute Leukemia

Image of trial facility.

Dinutuximab + Chemotherapy

for High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Lorlatinib + Standard Therapy

for Neuroblastoma

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Recruiting

2 awards

Phase 3

22 criteria

Image of trial facility.

DFMO Maintenance Therapy

for Neuroblastoma

This trial tests a medication called DFMO in patients with high-risk neuroblastoma who are in remission. The goal is to prevent the cancer from returning by stopping an enzyme that cancer cells need to grow. DFMO was initially developed as a cancer therapeutic agent but gained renewed interest as a preventive agent after showing effectiveness in inhibiting cancer development in rodent models.

Recruiting

1 award

Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Rady Children's Hospital - San Diego?

Where is Rady Children's Hospital - San Diego located?

Who should I call to ask about financial aid or insurance network?

What insurance does Rady Children's Hospital - San Diego accept?

What awards or recognition has Rady Children's Hospital - San Diego received?